Spots Global Cancer Trial Database for Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma
Official Title: Phase 1 Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Study ID: NCT04296461
Conditions
Interventions
Study Description
Brief Summary: This is an open-label, single-center Phase 1/2 study with a dose-escalation phase (Part 1) and a cohort expansion phase (Part 2) in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tri-Service General Hospital, Taipei, , Taiwan
Contact Details
Name: Ching-Liang Ho, MD
Affiliation: Tri-Service General Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
